Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 36

978 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
978
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

978 trials in L'hospitalet De Llobregat

Open in trial search

Skin squamous cell carcinoma metastatic+1

Not yet recruiting

Study of INCB099280 for Patients With Advanced Cutaneous Squamous Cell Carcinoma Not Suitable for Surgery or Radiotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Incb099280
  • Sponsor:Incyte Corp.

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg2 Monoclonal Antibody Against Interleukin-6
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Not yet recruiting

Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Merck Sharp & Dohme LLC

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Ischaemic stroke

Not yet recruiting

Study of ApTOLL for Treating Acute Ischemic Stroke in Patients Before Hospital Arrival

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aptamer-4Ft
  • Sponsor:Aptatargets S.L.

Ischaemic stroke

Not yet recruiting

Study on Redasemtide for Adults with Acute Ischemic Stroke Not Eligible for Standard Treatments

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Redasemtide
  • Sponsor:Shionogi B.V.

Triple negative breast cancer

Not yet recruiting

Study of ipatasertib with atezolizumab and chemotherapy in women with triple-negative breast cancer before surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Queen Mary University Of London

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.